ReviewCureus2025
Exploring Nadolol as a Therapeutic Option for Infantile Hemangioma: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of interventions for infantile hemangioma compared with oral propranolol: an updated systematic review and bayesian network meta-analysis.European journal of pediatrics · 2026Pooled it
- A Systematic Review and Meta-Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma.Journal of cosmetic dermatology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (IH) is a common vascular tumor of infancy, characterized by rapid early growth and gradual spontaneous involution. Propranolol remains first-line therapy for complicated IH but is limited by adverse effects and contraindications in some infants. Nadolol, a nonselective beta-adrenergic antagonist with a longer half-life and reduced CNS penetration, has been proposed as an alternative. Evidence suggests these pharmacokinetic properties may improve safety, reduce neurocognitive side effects, and enhance adherence while achieving comparable efficacy to propranolol. However, data are limited, particularly regarding long-term safety and standardized dosing protocols. Further controlled studies are needed to define nadolol's role in IH management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.